14.22

2.20% -0.32

After Hours: 14.40 0.18 +1.27%

Takeda Pharmaceutical Co Adr (TAK)

Overview News Price History Option Chain Discussions Forecast Dividend History

Takeda Pharmaceutical Co Adr stock is traded at $14.22, with a volume of 2.76M. It is down -2.20% in the last 24 hours and down -4.50% over the past month. Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Previous Close:

$14.54

Open:

$14.44

24h Volume:

2.76M

Relative Volume:

1.28

Market Cap:

$44.98B

Revenue:

$29.58B

Net Income/Loss:

$974.15M

P/E Ratio:

32.03

EPS:

0.444

Net Cash Flow:

$3.13B

1W Performance:

-4.50%

1M Performance:

-4.50%

6M Performance:

+2.38%

1Y Performance:

-8.08%

1-Day Range:

$14.18

$14.44

1-Week Range:

$14.18

$14.85

52-Week Range:

$12.57

$15.47

Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile

Name

Takeda Pharmaceutical Co Adr

Sector

Healthcare (1190)

Industry

Drug Manufacturers - Specialty & Generic (86)

Phone

Address

Employee

49,281

Twitter

@takedapharma

Next Earnings Date

2024-07-31

Latest SEC Filings

TAK's Discussions on Twitter

Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-23	Upgrade	BofA Securities	Neutral → Buy
Jul-19-22	Upgrade	Cowen	Market Perform → Outperform
Oct-07-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-19-21	Downgrade	JP Morgan	Overweight → Neutral
Nov-01-19	Initiated	Cowen	Market Perform
Aug-15-19	Downgrade	Daiwa Securities	Outperform → Neutral

View All

Takeda Pharmaceutical Co Adr Stock (TAK) Latest News

Sep 26, 2024

Taking a look at what insiders are doing to gauge the Takeda Pharmaceutical Co ADR (TAK)’s direction - Knox Daily

Sep 26, 2024

Tetra Tech, Inc. [TTEK] EVP, CFO makes an insider purchase of 36,830 shares worth 1.72 million. - Knox Daily

Sep 26, 2024

TAK’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle

Sep 26, 2024

Sep 22, 2024

Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.

Sep 22, 2024

Sep 16, 2024

Weekly Upgrades and Downgrades - InvestorPlace

Sep 16, 2024

Weekly Upgrades and Downgrades - MSN

Sep 16, 2024

Vatroslav Mateljic Appointed General Manager of Takeda Canada - Quantisnow

Sep 16, 2024

Sep 15, 2024

Ipsen provides update on CONTACT-02 Phase III trial in - GlobeNewswire

Sep 15, 2024

Sep 11, 2024

Celiac Disease Diagnostics Market to Reach US$ 1.42 Billion by 2034, Driven by 8.5% CAGR | Fact.MR Report - GlobeNewswire Inc.

Sep 11, 2024

Sep 09, 2024

ProSearch to Highlight Meta Skills, Legal Data Intelligence, and Emerging Data Sources at Upcoming Events - GlobeNewswire Inc.

Sep 09, 2024

Sep 06, 2024

Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production - Benzinga

Sep 06, 2024

Sep 05, 2024

Pseudarthrosis Treatment Market is Projected to Reach $1.37 Billion at a CAGR 4.6% by 2034 | Fact.MR Report - GlobeNewswire Inc.

Sep 05, 2024

Sep 04, 2024

Middle East & Africa Inflammatory Bowel Disease Treatment Market Size & Outlook, 2030 - Grand View Research

Sep 04, 2024

Sep 03, 2024

The UAE Inflammatory Bowel Disease Treatment Market Size & Outlook, 2030 - Grand View Research

Sep 03, 2024

Asia Pacific Inflammatory Bowel Disease Treatment Market Size & Outlook, 2030 - Grand View Research

Sep 03, 2024

Japan Inflammatory Bowel Disease Treatment Market Size & Outlook, 2030 - Grand View Research

Sep 03, 2024

Aug 28, 2024